| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Phil D | |
| Jansen VA | |||
| Payne RJ | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phage therapy | Q611870 |
| P304 | page(s) | 225-230 | |
| P577 | publication date | 2000-09-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Phage therapy: the peculiar kinetics of self-replicating pharmaceuticals | |
| P478 | volume | 68 |
| Q42253647 | A cocktail of in vitro efficient phages is not a guarantee for in vivo therapeutic results against avian colibacillosis |
| Q91787842 | Active bacteriophage biocontrol and therapy on sub-millimeter scales towards removal of unwanted bacteria from foods and microbiomes |
| Q36571896 | Bacteriophage Combinations Significantly Reduce Clostridium difficile Growth In Vitro and Proliferation In Vivo |
| Q37273445 | Bacteriophage biocontrol in animals and meat products |
| Q28217826 | Bacteriophage isolation from human saliva |
| Q33990300 | Bacteriophage latent-period evolution as a response to resource availability |
| Q38321117 | Bacteriophage secondary infection |
| Q38348303 | Bacteriophage therapy against Enterobacteriaceae |
| Q41389079 | Bacteriophage therapy and the mutant selection window |
| Q42045888 | Bacteriophage therapy to reduce salmonella colonization of broiler chickens |
| Q42780037 | Bacteriophage-Mediated Dispersal of Campylobacter jejuni Biofilms |
| Q36652581 | Bacteriophage: time to re-evaluate the potential of phage therapy as a promising agent to control multidrug-resistant bacteria |
| Q93127116 | Bacteriophages as Alternatives to Antibiotics in Clinical Care |
| Q36052554 | Bacteriophages as biocontrol agents in food. |
| Q64899610 | Bacteriophages engineered to display foreign peptides may become short-circulating phages. |
| Q47610097 | Basic Phage Mathematics |
| Q54332159 | Biosafety evaluation of bacteriophages for treatment of diarrhea due to intestinal pathogen Escherichia coli 3-2 infection of chickens. |
| Q42233716 | Characterization and genome analysis of the Bacillus cereus-infecting bacteriophages BPS10C and BPS13. |
| Q50016444 | Complete genome sequence analysis of bacterial-flagellum-targeting bacteriophage chi. |
| Q57279763 | Complete genomic sequence of the Vibrio alginolyticus bacteriophage Vp670 and characterization of the lysis-related genes, cwlQ and holA |
| Q41868063 | Coverage of diarrhoea-associated Escherichia coli isolates from different origins with two types of phage cocktails |
| Q44708928 | Development of a novel method of lytic phage delivery by use of a bacteriophage P22 site-specific recombination system |
| Q64110389 | Directed in Vitro Evolution of Therapeutic Bacteriophages: The Appelmans Protocol |
| Q49829450 | Does Treatment Order Matter? Investigating the Ability of Bacteriophage to Augment Antibiotic Activity against Staphylococcus aureus Biofilms |
| Q40948487 | Dynamics of Mycobacteriophage-Mycobacterial Host Interaction: Evidence for Secondary Mechanisms for Host Lethality |
| Q24803578 | Dynamics of success and failure in phage and antibiotic therapy in experimental infections |
| Q42012908 | Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae. |
| Q97529738 | Efficacy of phage cocktail AB-SA01 therapy in diabetic mouse wound infections caused by multidrug-resistant Staphylococcus aureus |
| Q42232404 | Enhancement of the antimicrobial properties of bacteriophage-K via stabilization using oil-in-water nano-emulsions |
| Q36015413 | Enumerating Virus-Like Particles and Bacterial Populations in the Sinuses of Chronic Rhinosinusitis Patients Using Flow Cytometry |
| Q42811256 | Evidence for a phage proliferation threshold? |
| Q39544046 | Evolutionary dynamics of separate and combined exposure of Pseudomonas fluorescens SBW25 to antibiotics and bacteriophage |
| Q24685170 | Experimental phage therapy against Staphylococcus aureus in mice |
| Q41115248 | Genome sequencing and analysis of an Escherichia coli phage vB_EcoM-ep3 with a novel lysin, Lysep3. |
| Q63762111 | Host Resistance, Genomics and Population Dynamics in a Enteritidis and Phage System |
| Q38169356 | Hurdles in bacteriophage therapy: deconstructing the parameters. |
| Q47422573 | Interaction of Bacteriophages with Mammalian Cells |
| Q61813504 | Interactions between Bacteriophage, Bacteria, and the Mammalian Immune System |
| Q37187438 | Microneedle-mediated transdermal bacteriophage delivery |
| Q42177963 | Modeling phage induced bacterial disinfection rates and the resulting design implications. |
| Q47200464 | Models of phage growth and their applicability to phage therapy |
| Q24563742 | Natural solution to antibiotic resistance: bacteriophages 'The Living Drugs' |
| Q42369908 | Newly Isolated Bacteriophages from the Podoviridae, Siphoviridae, and Myoviridae Families Have Variable Effects on Putative Novel Dickeya spp. |
| Q39686807 | Overcoming the phage replication threshold: a mathematical model with implications for phage therapy |
| Q36171271 | Phage Therapy - Everything Old is New Again |
| Q93181959 | Phage Therapy Regulation: From Night to Dawn |
| Q92960573 | Phage Therapy with a Focus on the Human Microbiota |
| Q38911928 | Phage Therapy: Future Inquiries |
| Q49484033 | Phage Therapy: Various Perspectives on How to Improve the Art. |
| Q34702499 | Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad model |
| Q39906833 | Phage therapy of staphylococcal chronic osteomyelitis in experimental animal model |
| Q92468490 | Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review |
| Q38230407 | Phage therapy: eco-physiological pharmacology |
| Q34254407 | Phage treatment of human infections. |
| Q90720289 | Phage-Antibiotic Combination Treatments: Antagonistic Impacts of Antibiotics on the Pharmacodynamics of Phage Therapy? |
| Q51693539 | Pharmacoecology: a new name for an old science. |
| Q35089166 | Pharmacokinetic principles of bacteriophage therapy. |
| Q35709197 | Population and evolutionary dynamics of phage therapy |
| Q35211072 | Population dynamics of a Salmonella lytic phage and its host: implications of the host bacterial growth rate in modelling |
| Q33396975 | Quantitative models of in vitro bacteriophage-host dynamics and their application to phage therapy. |
| Q42325471 | Real-time quantitative PCR to discriminate and quantify lambdoid bacteriophages of Escherichia coli K-12 |
| Q42153895 | Reduction of invasive bacteria in ethanol fermentations using bacteriophages. |
| Q42241966 | Safety and efficacy of topical bacteriophage and ethylenediaminetetraacetic acid treatment of Staphylococcus aureus infection in a sheep model of sinusitis |
| Q92146385 | Targeting antibiotic resistant bacteria with phage reduces bacterial density in an insect host |
| Q47562681 | Temperate phages as self-replicating weapons in bacterial competition. |
| Q57952638 | The Diversity of Bacterial Lifestyles Hampers Bacteriophage Tenacity |
| Q64251258 | The Preclinical and Clinical Progress of Bacteriophages and Their Lytic Enzymes: The Parts are Easier than the Whole |
| Q38193804 | The factors affecting effectiveness of treatment in phages therapy |
| Q36135134 | The role of regulated clinical trials in the development of bacteriophage therapeutics |
Search more.